Loading
Cabaletta Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 21 Jan 2026.
Cabaletta Bio, Inc.: what insiders have been doing
This page follows insider dealings at Cabaletta Bio, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 8 filings signed by 8 insiders.
Only purchases show up on the open market, 8 purchases in all worth €253k, filed by 8 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €86k, bought by Nichtberger Steven and made public on 21 January 2026. On the buying side, the filings list 6 senior executives and 2 chief executives among the declarants.
Within a 30-day window, 8 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 21 January 2026, which is 270 days ago.
With 8 filings in twelve months, the company is quieter than the median of 19 filings across the 5,816 companies we follow on the same exchange. Our records for Cabaletta Bio, Inc. go back to 2021, with 14 purchases and 4 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
28
Thresholds
n/a
Buy Volume
€594,257
14 ops. · all time
Sell Volume
€8M
4 ops. · all time
Who traded when
BuySaleCatherine Bollard1 buy
David J. Chang1 buy
Gwendolyn Binder1 buy
Mark Simon1 buy
Michael Gerard1 buy
Shawn Tomasello1 buy
+2 other insiders
Since the insiders bought
- +7.8%Entry US$2.94 · Close at T+90 US$3.17
- +7.8%Entry US$2.94 · Close at T+90 US$3.17
- +7.8%Entry US$2.94 · Close at T+90 US$3.17
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.71
Analyst consensus
8 analysts1.50/5
US$4.00Target US$13.38(+394%)US$30.00
Income statement
EBITDA-US$164.2M
Net income-US$167.9M0.0% margin
Valuation
PER (forward)-1.9x
P/Book2.4x
Beta3.25
Balance sheet & cash
Market capUS$441.9M
Total debtUS$27.1M
Free Cash Flow-US$132.3M
Debt / Equity26%
Profitability & ownership
ROE-156.0%
ROA-71.6%
% insiders1.0%
% institutions78.0%
Last declaration on 21 January 2026
Declarations28 total
22,170 shares@ US$2.265100.0% of flowCommon StockSEC:0001193125-26-018323:0
Canonical exit: 21 Apr 2026 (T+90)
8,800 shares@ US$2.26100.0% of flowCommon StockSEC:0001193125-26-018327:0
Canonical exit: 21 Apr 2026 (T+90)
11,312 shares@ US$2.18917.6% of flowCommon StockSEC:0001193125-26-018325:0
Canonical exit: 21 Apr 2026 (T+90)
22,725 shares@ US$2.2144100.0% of flowCommon StockSEC:0001193125-26-018324:0
Canonical exit: 21 Apr 2026 (T+90)
4,405 shares@ US$2.266189.4% of flowCommon StockSEC:0001193125-26-018319:0
Canonical exit: 21 Apr 2026 (T+90)
45,000 shares@ US$2.239530.2% of flowCommon StockSEC:0001193125-26-018318:0
Canonical exit: 21 Apr 2026 (T+90)
6,600 shares@ US$2.2696100.0% of flowCommon StockSEC:0001193125-26-018316:0
Canonical exit: 21 Apr 2026 (T+90)
11,061 shares@ US$2.283815.6% of flowCommon StockSEC:0001193125-26-018317:0
Canonical exit: 21 Apr 2026 (T+90)
11,000 shares@ US$1.013.7% of flowCommon StockSEC:0000950170-24-005888:0
11,000 shares@ US$1.013.6% of flowCommon StockSEC:0000950170-23-071689:0
11,000 shares@ US$1.013.7% of flowCommon StockSEC:0000950170-23-065521:0
11,000 shares@ US$1.013.8% of flowCommon StockSEC:0000950170-23-054234:0
11,000 shares@ US$1.013.7% of flowCommon StockSEC:0000950170-23-049005:0
300 shares@ US$13.82331.4% of flowCommon StockSEC:0000950170-23-043920:2
11,000 shares@ US$1.013.7% of flowCommon StockSEC:0000950170-23-043920:0
10,700 shares@ US$13.405247.2% of flowCommon StockSEC:0000950170-23-043920:1
11,000 shares@ US$1.013.6% of flowCommon StockSEC:0000899243-23-017452:0
11,000 shares@ US$1.013.6% of flowCommon StockSEC:0000899243-23-016147:0
22,000 shares@ US$1.017.4% of flowCommon StockSEC:0000899243-23-013455:0
8,127 shares@ US$1.24923.7% of flowCommon StockSEC:0000899243-22-033850:0
Canonical exit: 17 Jan 2023 (T+90)
1,000 shares@ US$0.993510.6% of flowCommon StockSEC:0000899243-22-033783:0
Canonical exit: 16 Jan 2023 (T+90)
118,000 shares@ US$0.97784.4% of flowCommon StockSEC:0000899243-22-033781:0
Canonical exit: 16 Jan 2023 (T+90)
141,873 shares@ US$0.993950.2% of flowCommon StockSEC:0000899243-22-033779:0
Canonical exit: 16 Jan 2023 (T+90)
50,000 shares@ US$0.9924100.0% of flowCommon StockSEC:0000899243-22-033782:0
Canonical exit: 16 Jan 2023 (T+90)
20,000 shares@ US$0.99477.2% of flowCommon StockSEC:0000899243-22-033780:0
Canonical exit: 16 Jan 2023 (T+90)
25 of 28 declarations
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ in the United States (United States), focused on developing targeted cell therapies for autoimmune diseases. Founded in 2017 and emerging from the University of Pennsylvania, the company is headquartered in Philadelphia, Pennsylvania. Its origin story matters strategically: Cabaletta was built around translating academic immunology and cell-therapy expertise into a platform aimed at delivering durable, potentially curative treatment responses rather than long-term symptom control. ([cabalettabio.com](https://www.cabalettabio.com/about?utm_source=openai))
The company’s lead asset is rese-cel (resecabtagene autoleucel), an autologous CD19-directed CAR-T therapy designed to deplete pathogenic B cells and reset immune dysfunction in autoimmune disease. Cabaletta is advancing rese-cel through its RESET (REstoring SElf-Tolerance) clinical development program, which spans multiple disease areas including systemic lupus erythematosus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris. This gives the company a platform-like strategy: one product concept, multiple indications, and the potential for cross-indication clinical and commercial leverage. At the same time, this also means the investment case remains highly dependent on clinical readouts, regulatory alignment, and manufacturing execution. ([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/148/cabaletta-bio-reports-first-quarter-2026-financial-results?utm_source=openai))
Read moreShow less
From a competitive standpoint, Cabaletta occupies a differentiated niche. It is one of the more focused developers applying CAR-T to autoimmune disease, a segment that remains far less crowded than oncology but also far less proven commercially. The company has been emphasizing practical treatment advantages such as a favorable safety profile that may support outpatient use, along with a manufacturing model intended to improve scalability and capital efficiency. In April 2026, Cabaletta announced a 10-year commercial supply agreement with Cellares for automated manufacturing of rese-cel, which is an important step toward potential launch readiness and supply-chain de-risking. ([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/145/cabaletta-bio-and-cellares-announce-10-year-commercial?utm_source=openai))
Operationally, Cabaletta’s footprint is centered in Philadelphia, with clinical activity concentrated in the United States and supporting international visibility through scientific conferences and select trial activity in Europe. Recent company updates in 2025 and 2026 show a business moving from pure R&D toward more explicit pre-commercial planning: new clinical datasets have been presented, 2026 strategic priorities were outlined, and management reiterated a target of a BLA submission in 2027 for myositis. For investors, CABA represents a high-risk, high-upside U.S. NASDAQ biotech story anchored in autoimmune cell therapy innovation, but still subject to the binary nature of late-stage development outcomes. ([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/148/cabaletta-bio-reports-first-quarter-2026-financial-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
